DENVER, Nov. 10, 2016 -- Cannabis and CBD innovator, Elixinol will be expanding its partnerships and announcing new product lines at the 2016 Marijuana Business Conference and Expo November 16-18 in Las Vegas. The 3-day business-to-business conference known also as the MJ Biz Conference, will include cannabis leaders, like Elixinol, from around the United States.
Elixinol is title sponsor of the The Mixer, an event where 100% of tickets sales will be donated to non-profits working at the national and federal level to reform cannabis laws, advocate patient access and reduce harms caused by the nation’s current drug enforcement approach.
“Because Elixinol CBD products don’t have the effects of THC, Elixinol CBD is already legal in all 50 states and available in 40 countries, but recent election results in 9 states including Nevada, increased access to cannabis,” said Chris Husong Director of Sales and Marketing for Elixinol.
“We support normalizing cannabis and increased access for patients around the world,” he continued.
Elixinol will be sharing cannabis and CBD insights with an estimated 7,500 industry leaders and will have 3 new product lines available including its topical product Rescue Balm and Respira, its newest tincture suitable for vaping.
“Because education is such an important part of our company culture, we wanted to be able to share the latest formulation and delivery CBD innovations with the cannabis industry,” says Husong.
The entire Elixinol product line will be at the conference. To schedule interviews and see the new product lines first-hand, please email Chris Husong for a private appointment or visit booth #748 on the tradeshow floor.
“The Marijuana Business Conference and Expo is a great closing to our best year yet which included several new product lines and expansion into new markets like Japan and the UK,” said Husong.
“We’ve been around the world this year and we’re very excited to add this conference to our plans and expect it will be a great experience for all involved,” he continued.
About Elixinol:
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD manufacturers with a proven track record of consulting, growing and manufacturing high quality hemp, laboratory testing and quality control. A global leader in distribution and cannabis education, Elixinol distributes CBD products in the United States, Japan, UK and Puerto Rico. Elixinol and its global partners, including Elixinol Japan, recently introduced World Hemp Conference Innovation winner hemp oil Liposomes, with superior absorption and real fruit flavor and the Xpen, the most precise CBD oil delivery system available. More information available at: elixinol.com
Media Contact: Chris Husong Elixinol 408-420-8890 (m) [email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



